PureTech creates resTORbio subsidiary to in-license Novartis aging-related programs
Executive Summary
PureTech Health PLC, through a newly created, 58%-owned subsidiary called resTORbio Inc., will collaborate with Novartis Institutes for BioMedical Research Inc. to advance two Novartis mechanistic target of rapamycin complex 1 (mTORC1) pathway programs in multiple aging-related conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice